ArticleCureus2025
The Efficiency of Systemic Dapsone in the Treatment of Acne Fulminans: A Clinical Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne is a benign, complex, multifactorial disease resulting from hormonal, genetic, and environmental factors. It is considered a pubertal phenomenon and mainly affects adolescents, although some atypical cases can be observed in newborns and adults. Diagnosis is often straightforward, but in some cases, management can be difficult, with dramatic psychological and social consequences. Due to its antibiotic and immunomodulatory effects, dapsone has become an indispensable treatment in dermatology, particularly for severe acne resistant to conventional therapies. We report the case of a 31-year-old patient with acne fulminans, resistant to oral corticosteroids and isotretinoin, who was treated with 100 mg/day of dapsone, resulting in complete resolution of acne after six months of treatment. No side effects or recurrences were observed after three years of semi-annual follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.